More on MRNA
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $202.63 |
|
|||
| Open | $196.69 | ||||
| 52 Wk High | $0.52 | ||||
| 52 Wk Low | $0.08 | ||||
| Day High | $203.47 | ||||
| Day Low | $183.00 | ||||
| P/E | N/A | ||||
| EPS | $-3.80 | ||||
| Volume | 9,160,524 | ||||
- Moderna shares continue to fall after early cancer vaccine data leak
- Citi reiterates Sell rating on Moderna with $80 price target
- Moderna Named a Top Employer by Science for Twelfth Consecutive Year
- Moderna (MRNA) call put ratio 1 call to 1.4 puts amid wide share price movement
- RBC Capital Reiterates Sector Perform Rating on Merck (MRK)
- Citi keeps Sell rating on Moderna after melanoma trial data, PT $80
- Merck and Moderna report Phase 3 melanoma trial results
- Moderna (MRNA) call put ratio 1 call to 1.6 puts as share price down 22%
- Merck and Moderna melanoma drug combo cuts recurrence risk by 42%
- Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
Entities mentioned with mrna
- FDA | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- Options | View Related Stories »
- Pre Market Movers | View Related Stories »
- Show More...
